Analysis of KLF5 copy number variation revealed two major patterns: heterozygous amplification, primarily in gastrointestinal, lung adenocarcinoma, and bladder cancers, and heterozygous deletion with a broader distribution across multiple cancer types. This evidence concerns the gene KLF5 and urinary bladder cancer.